Trump et al. focus on NIH, cancer—and how peer review is done

HHS withdraws 340B drug rebate pilot program

HHS is withdrawing the “340B Rebate Model Pilot Program” that was intended to go into effect on Jan. 1, according to a joint motion filed last week.

After a brief government shutdown, FY26 funding bill is signed into law
NIH gets $415M raise, NCI gets $128M more, CDMRP funding largely restored

On Feb. 3, the House of Representatives passed the Senate Amendment to H.R. 7148, the Consolidated Appropriations Act, 2026, by a vote of 217 to 214. Later that day, President Donald Trump signed the bill into law, officially ending the brief partial government shutdown that began on Jan. 31.

NIH’s Bhattacharya acknowledges absence of causal link between vaccines and autism

Pressed by Sen. Bernie Sanders (I-VT), NIH Director Jay Bhattacharya acknowledged that he is not aware of any study pointing to a causal link between vaccines and autism.

“Basic Experimental Studies Involving Humans” no longer classified as clinical trials at NIH in an effort to reduce administrative burden

NIH announced Jan. 29 that “Basic Experimental Studies Involving Humans,” also called BESH, will no longer be considered clinical trials and will therefore no longer be subject to the requirements under the NIH definition of a clinical trial, including registration and reporting requirements in ClinicalTrials.gov.

February 06, 2026

Vol.52 No.05

By Jacquelyn Cobb

Podcast The Directors

The Directors: Gary Schwartz and Ramon Parsons on the best of times (for science), the worst of times (for funding)
Cancer centers fund small grants to boost morale amid low paylines

As NCI paylines drop to 4%, cancer centers are tapping into their institutional funds to provide “bridge funding,” typically in $50,000 to $100,000 increments, to enable investigators to keep their labs open until better times return—next year God willing.

January 30, 2026

Vol.52 No.04

By Paul Goldberg and Claire Marie Porter

Cancer Policy

NIH suspends new embryonic stem cell line submissions

NIH is suspending the addition of new human embryonic stem cell lines to the Human Embryonic Stem Cell Registry, all while looking for alternatives. The agency also issued a request for information on “emerging biotechnologies to reduce or potentially replace remaining research reliance on human embryonic stem cells.”

January 30, 2026

Vol.52 No.04

By Sara Willa Ernst

Trump et al. focus on NIH, cancer—and how peer review is done

YOU MAY BE INTERESTED IN

HHS withdraws 340B drug rebate pilot program

After a brief government shutdown, FY26 funding bill is signed into law
NIH gets $415M raise, NCI gets $128M more, CDMRP funding largely restored

NIH’s Bhattacharya acknowledges absence of causal link between vaccines and autism

“Basic Experimental Studies Involving Humans” no longer classified as clinical trials at NIH in an effort to reduce administrative burden

The Directors: Gary Schwartz and Ramon Parsons on the best of times (for science), the worst of times (for funding)
Cancer centers fund small grants to boost morale amid low paylines

NIH suspends new embryonic stem cell line submissions

Renew today!

Subscriber content

Never miss an issue!

Login

Trump et al. focus on NIH, cancer—and how peer review is done

YOU MAY BE INTERESTED IN

HHS withdraws 340B drug rebate pilot program

After a brief government shutdown, FY26 funding bill is signed into lawNIH gets $415M raise, NCI gets $128M more, CDMRP funding largely restored

NIH’s Bhattacharya acknowledges absence of causal link between vaccines and autism

“Basic Experimental Studies Involving Humans” no longer classified as clinical trials at NIH in an effort to reduce administrative burden

The Directors: Gary Schwartz and Ramon Parsons on the best of times (for science), the worst of times (for funding)Cancer centers fund small grants to boost morale amid low paylines

NIH suspends new embryonic stem cell line submissions

Never miss an issue!

Login

After a brief government shutdown, FY26 funding bill is signed into law
NIH gets $415M raise, NCI gets $128M more, CDMRP funding largely restored

The Directors: Gary Schwartz and Ramon Parsons on the best of times (for science), the worst of times (for funding)
Cancer centers fund small grants to boost morale amid low paylines